Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Angeliq · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm 2 | PLACEBO_COMPARATOR | - |
| Arm 1 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Arm 4 | EXPERIMENTAL | - |
| Arm 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Angeliq (Drospirenone/17ß-estradiol, BAY86-4891) | DRUG | Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval. |
| Placebo | DRUG | Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval. |
Inclusion Criteria: * Postmenopausal Korean women suffering from hot flushes Exclusion Criteria: * Standard exclusion criteria for HRT clinical trials had to be obeyed, including current or history of hormone dependent malignant disease, thromboembolic disorders, abnormal cervical smear, undiagno...
Angeliq is a small molecule drug being developed by Bayer AG for the treatment of hypertension and vasomotor symptoms in postmenopausal women. It is currently in Phase 3 clinical development and is considered investigational, meaning it has not been approved for use.
Angeliq is developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker BAYRY. The drug is being studied for cardiovascular and menopausal indications, including hypertension and vasomotor symptoms.
Angeliq is in Phase 3 clinical development. It has completed two Phase 3 trials, one in postmenopausal hypertensive women and another in Korean postmenopausal women with vasomotor symptoms. The drug remains investigational and is not yet approved.
Angeliq has completed two Phase 3 trials. NCT00102141 studied its effect on blood pressure in 750 postmenopausal hypertensive women, and NCT00651599 evaluated treatment of vasomotor symptoms in 90 Korean postmenopausal women. Both trials were randomized, double-blind, and placebo-controlled.
Angeliq is a distinct drug product developed by Bayer AG. No alternative names have been associated with it in clinical trial records. It is being studied specifically for hypertension and vasomotor symptoms in postmenopausal women.